Latest News and Press Releases

中国苏州和美国旧金山, May 26, 2021 (GLOBE NEWSWIRE) --...

SAN FRANCISCO, Calif. and SUZHOU, China, May 25, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to...

-筛选到与临床疗效和靶点结合相关的预测性生物标志物与药效生物标志物- -ADG106单一疗法安全性良好- 中国苏州和美国旧金山, May 20, 2021 (GLOBE NEWSWIRE) --...

-Identified a predictive biomarker and two pharmacodynamic biomarkers that correlate with clinical efficacy and target engagement -ADG106, a fully human, ligand-blocking, agonistic anti-CD137...

SAN FRANCISCO and SUZHOU, China, April 13, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the...

中国苏州和美国旧金山, April 13, 2021 (GLOBE NEWSWIRE) -- 天演药业（以下简称“公司”或“天演”）（纳斯达克股票代码：ADAG）是一家平台驱动的临床阶段生物制药公司，致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。公司今日宣布在今年的美国癌症研究协会（AACR）年会上公布其第一个安全抗体（SAFEbody™）项目ADG126的临床前数据。 ...

- 成功完成首次公开募股，总集资额约1.61亿美元 -- 公布了抗CD137和两个抗CTLA-4产品的临床数据 -- 将五个早期发现项目推进至新药申请的临床前研究阶段 -- 与学术界及行业内的多个合作伙伴建立了商业合作关系 -- 进一步强化了管理团队 - 中国苏州和美国旧金山, April 02, 2021 (GLOBE NEWSWIRE) --...

- Successfully completed Initial Public Offering raising approximately US$161 million in gross proceeds--Reported clinical data for anti-CD137 and two anti-CTLA-4 programs--Advanced five discovery...

-新表位抗体（NEObody™) 候选药物ADG 116在当前I期临床试验中显示出良好的耐受性-- ADG 116药理机制的早期临床验证支持其全球临床试验扩展- 中国苏州和美国旧金山, March 29, 2021 (GLOBE NEWSWIRE) --...

-NEObody™ product candidate ADG116 has been well tolerated in ongoing Phase 1 clinical trial- -Promising pharmacodynamic biomarker signals demonstrate clinical proof of mechanism--Poised for global...